{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:25:21Z","timestamp":1790259921783,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are commonly administered for HCC as combination therapy, including combined anti-angiogenic and immunotherapy combination therapy. We report a case of a primary massive HCC patient with portal hepatic vein tumor thrombus who had a good response to atezolizumab in combination with bevacizumab, following progression of disease on combined immunotherapy with pembrolizumab and lenvatinib. This case demonstrates for the first time that an HCC patient who is resistant to anti-PD-1 antibody immunotherapy can benefit from anti-PD-L1 antibody immunotherapy, providing a potentially promising strategy for the treatment of HCC.<\/jats:p>","DOI":"10.3389\/fimmu.2021.712351","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T14:08:30Z","timestamp":1629814110000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody"],"prefix":"10.3389","volume":"12","author":[{"given":"Gang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1190-5681","article-title":"Response of Advanced HCC to Pembrolizumab and Lenvatinib Combination Therapy Despite Monotherapy Failure","volume":"58","author":"Schulte","year":"2020","journal-title":"Z Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33609","article-title":"Immune-Related Adverse Events Predict Responses to PD-1 Blockade Immunotherapy in Hepatocellular Carcinoma","volume":"149","author":"Lu","year":"2021","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1038\/s41467-020-19810-w","article-title":"PD-L1 Blockade in Combination With Inhibition of MAPK Oncogenic Signaling in Patients With Advanced Melanoma","volume":"11","author":"Ribas","year":"2020","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","article-title":"Immunotherapy for Hepatocellular Carcinoma","volume":"470","author":"Zongyi","year":"2020","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0026","article-title":"Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait","volume":"13","author":"Rizzo","year":"2021","journal-title":"Immunotherapy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","article-title":"Therapeutic PD-L1 Antibodies Are More Effective Than PD-1 Antibodies in Blocking PD-1\/PD-L1 Signaling","volume":"9","author":"De Sousa Linhares","year":"2019","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2004.225.1225","article-title":"Massive Hepatocellular Carcinoma in Dogs: 48 Cases (1992\u20132002)","volume":"225","author":"Liptak","year":"2004","journal-title":"J Am Vet Med Assoc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/00480169.2017.1319304","article-title":"Impact of Surgical Margins on Survival of 37 Dogs With Massive Hepatocellular Carcinoma","volume":"65","author":"Matsuyama","year":"2017","journal-title":"N Z Vet J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12893-020-00952-z","article-title":"The Technique of 3D Reconstruction Combining With Biochemistry to Build an Equivalent Formula of Indocyanine Green (ICG) Clearance Test to Assess the Liver Reserve Function","volume":"20","author":"Zheng","year":"2020","journal-title":"BMC Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919862692","article-title":"Immunotherapy for Hepatocellular Carcinoma: Recent Advances and Future Perspectives","volume":"11","author":"Xu","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12708","article-title":"Combination Therapy Strategies for Improving PD-1 Blockade Efficacy: A New Era in Cancer Immunotherapy","volume":"283","author":"Chowdhury","year":"2018","journal-title":"J\u00a0Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13543","article-title":"Retreatment With Anti-PD-L1 Antibody in Advanced Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies","volume":"39","author":"Fujita","year":"2019","journal-title":"Anticancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.01.027","article-title":"Atezolizumab After Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered After Anti-PD-1-Related Immune Toxicities","volume":"13","author":"Swami","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-236101","article-title":"Complete Response With Anti-PD-L1 Antibody Following Progression on Anti-PD-1 Antibody in Advanced Non-Small Cell Lung Cancer","volume":"13","author":"Singh","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and Nivolumab\/Pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580241","article-title":"Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-Of-Concept Study","volume":"10","author":"Lyu","year":"2020","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and Durvalumab for Previously Treated, Advanced Non-Small-Cell Lung Cancer, Gastric\/Gastro-Oesophageal Junction Adenocarcinoma, or Hepatocellular Carcinoma: An Open-Label, Phase Ia\/b Study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.712351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T14:08:32Z","timestamp":1629814112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.712351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2021.712351"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.712351","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"article-number":"712351"}}